GeoVax Labs, Inc. (NASDAQ:GOVX) Given Consensus Recommendation of “Buy” by Analysts

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX) have been given a consensus rating of “Buy” by the six brokerages that are covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $13.25.

A number of brokerages recently issued reports on GOVX. Alliance Global Partners started coverage on GeoVax Labs in a report on Monday, November 11th. They issued a “buy” rating and a $15.00 target price on the stock. Noble Financial boosted their target price on GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a research note on Monday, August 19th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of GeoVax Labs in a research note on Friday. Finally, EF Hutton Acquisition Co. I upgraded GeoVax Labs to a “strong-buy” rating in a research report on Tuesday, July 23rd.

GeoVax Labs Stock Performance

Shares of NASDAQ GOVX opened at $2.43 on Monday. The firm has a 50 day moving average price of $2.37 and a 200 day moving average price of $2.60. GeoVax Labs has a 52-week low of $1.09 and a 52-week high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.38. The firm had revenue of $2.79 million for the quarter, compared to the consensus estimate of $1.84 million. During the same quarter in the prior year, the firm earned ($4.80) EPS. On average, sell-side analysts forecast that GeoVax Labs will post -5.1 earnings per share for the current fiscal year.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.